Paroxetine in the treatment of obsessive-compulsive disorder: Randomized, double-blind, placebo-controlled study in Japanese patients

Psychiatry and Clinical Neurosciences

Volumn 58, Issue 4, 2004, Pages 427-433

  Kamijima, Kunitoshi ^a   Murasaki, Mitsukuni ^c   Asai, Masahiro ^d   Higuchi, Teruhiko ^b   Nakajima, Teruo ^e   Taga, Chiaki ^f   Matsunaga, Hisato ^g  

^a SHOWA UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b NATIONAL INSTITUTE OF MENTAL HEALTH   (Japan)

^c Institute of CNS Pharmacology   (Japan)

^d Kaichi International University   (Japan)

^e BUKKYO UNIVERSITY   (Japan)

^f KYOTO SECOND RED CROSS HOSPITAL   (Japan)

^g OSAKA CITY UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

Japan; Obsessive compulsive disorder; Paroxetine

Indexed keywords

PAROXETINE; PLACEBO; SEROTONIN UPTAKE INHIBITOR;

ABDOMINAL PAIN; ADOLESCENT; ADULT; AGED; ANOREXIA; APATHY; ARTICLE; BRONCHITIS; CLINICAL TRIAL; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIAGNOSTIC AND STATISTICAL MANUAL OF MENTAL DISORDERS; DIARRHEA; DISEASE SEVERITY; DIZZINESS; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; EJACULATION DISORDER; FEMALE; HAMILTON SCALE; HEADACHE; HUMAN; INSOMNIA; JAPAN; MAJOR CLINICAL STUDY; MALAISE; MALE; MULTICENTER STUDY; NAUSEA; OBSESSIVE COMPULSIVE DISORDER; RANDOMIZED CONTROLLED TRIAL; RATING SCALE; SIDE EFFECT; SOMNOLENCE; SUICIDE ATTEMPT; SYMPTOM; TREMOR; YALE BROWN OBSESSIVE COMPULSIVE SCALE;

ADOLESCENT; ADULT; AGED; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; FEMALE; HUMANS; JAPAN; MALE; MIDDLE AGED; OBSESSIVE-COMPULSIVE DISORDER; PAROXETINE; PERSONALITY INVENTORY; PSYCHOMETRICS; SEROTONIN UPTAKE INHIBITORS; TREATMENT OUTCOME;

EID: 4243064029     PISSN: 13231316     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1440-1819.2004.01278.x     Document Type: Article

References (21)

1. Zohar J, Westenberg HGM, Judge R. Anxiety disorders: a review of tricyclic antidepressants and selective serotonin reuptake inhibitors. Acta Psychiatr. Scand. 2000; 101 (Suppl. 403): 39-49.
2. Goodman WK. Obsessive-compulsive disorder: diagnosis and treatment. J. Clin. Psychiatry 1999; 60 (Suppl. 18): 27-32.
3. de Sliva P, Rachman S. The Facts: Obsessive Compulsive Disorder. Life Science Publishing, Tokyo, 2002 (in Japanese).
4. Van Renynghe de Voxvrie G. Use of anafranil (G34586) in obesessive nueroses. Acta Neurol. Psychiatr. Belg. 1968; 68: 787-792.
5. March JS, Frances A, Kahn DA, Carpenter D (eds). The Expert Consensus Guideline Series: Treatment of Obssesive-Compulsive Disorder. J. Clin. Psychiatry 1997; 58 (Suppl. 4): 1-72.
6. Oehrberg S, Christiansen PE, Behnke K et al. Paroxetine in the treatment of panic disorder: a randomised, double-blind, placebo-controlled study. Br. J. Psychiatry 1995; 167: 374-379.
7. Ballenger JC, Wheadon DE, Steiner M et al. Double-blind, fixed-dose, placebo-controlled study of paroxetine in the treatment of panic disorder. Am. J. Psychiatry 1998; 155: 36-42.
8. Zohar J, Judge R. Paroxetine versus clomipramine in the treatment of obsessive-compulsive disorder: OCD Paroxetine Study Investigators. Br. J. Psychiatry 1996; 169: 468-474.
9. Stein MB, Liebowitz MR, Lydiard RB et al. Paroxetine treatment of generalised social phobia (social anxiety disorder): a randomised controlled trial. JAMA 1998; 280: 708-713.
10. Baldwin D, Bobes J, Stein DJ et al. Paroxetine in social phobia/social anxiety disorder. Randomised, double-blind, placebo-controlled study. Paroxetine Study Group. Br. J. Psychiatry 1999; 175: 120-126.
11. Allgulander C. Paroxetine in social anxiety disorder: a randomized placebo-controlled study. Acta Psychiatr. Scand. 1999; 100: 196-198.
12. Pollack MH, Zaninelli R, Goddard A et al. Paroxetine in the treatment of generalised anxiety disorder: results of a placebo-controlled, flexible-dosage trial. J. Clin. Psychiatry 2001; 62: 305-307.
13. Rocca P, Fonzo V, Scotta M et al. Paroxetine efficacy in the treatment of generalised anxiety disorder. Acta Psychiatr. Scand. 1997; 95: 444-450.
14. Marshall RD, Beebe KL, Oldham M et al. Efficacy and safety of paroxetine treatment for chronic PTSD: a fixed-dose, placebo-controlled study. Am. J. Psychiatry 2001; 158: 1982-1988.
15. Tucker P, Zaninelli R, Yehuda R et al. Paroxetine in the treatment of chronic posttraumatic stress disorder: results of a placebo-controlled, flexible-dosage trial. J. Clin. Psychiatry 2001; 62: 860-868.
16. Nakajima T, Nakamura M, Taga T et al. Study on reliability and validity of Japanese version of Yale-Brown Obsessive Compulsive Scale (JY-BOCS). Clin. Eval. 1993; 21: 491-498.
17. Grimsley SR, Jann MW. Paroxetine, sertraline, and fluvoxamine: new selective serotonin reuptake inhibitors. Drugs Rev. 1992; 11: 930-957.
18. Miura S, Koyama T, Asai M et al. Clinical evaluation of paroxetine HCl, a selective serotonin reuptake inhibitor, in the treatment of depression or depressive episode: double-blind, parallel group study with amitriptyline HCl. Jpn Pharmacol. Ther. 2000; 28 (Suppl.): 187-210.
19. Tsutsui S, Okuse T, Sasaki D et al. Clinical evaluation of paroxetine HCl, a selective serotonin reuptake inhibitor, in the treatment of depression or depressive episode: double-blind, parallel group study with tazodone HCl. Jpn Pharmacol. Ther. 2000; 28 (Suppl.): 161-185.
20. Jenike MA. An update on obsessive-compulsive disorder. Bull. Menninger Clin. 2001; 65: 4-25.
21. Boyer WF, Blumhardt CL. The safety profile of paroxetine. J. Clin. Psychiatry 1992; 53 (Suppl. 2): 61-66.